The Pharmaceutical Industry in in transition:

• $60 billion of US pharma patent revenue will expire in 2012
• Decline in FDA drug approvals
• Surge of the generics which now accounts for 3 in 4 pills
• Shift to the stakeholder payer model puts market access at centre stage
• Leaner and more agile pharma companies
• 50,000+ senior level redundancies in the US alone
• Even more pressure on those retained
• Huge opportunities in emerging markets‘Your business never stops evolving why should your learning?’